Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Here, FLT3 is linked to acute myeloid leukemia.